Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 15/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 11/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993923 | 0.94 | SLC6A4 (0.88) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL5763468 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL5126491 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4481068 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4486883 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4483132 | 0.89 | SLC6A4 (0.87) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4495016 | 0.88 | SLC6A4 (0.85) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4486818 | 0.86 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4480782 | 0.85 | SLC6A4 (0.73) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 | |
| Fumaric Acid SCHEMBL5995768 | 0.84 | SLC6A4 (0.82) | SLC6A4SLC6A2CYP2D6KCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | claimed |
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A4 3/4885SLC6A2 1/4885CYP2D6 231/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A4 3/4885SLC6A2 1/4885CYP2D6 945/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A4 2/4885SLC6A2 1/4885CYP2D6 1256/4885 |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A4 5/4885SLC6A2 1/4885CYP2D6 97/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SLC6A4 2/4885SLC6A2 1/4885CYP2D6 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.